17 completed, 5 terminated, 3 active not recruiting. 25 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 17, Terminated 5, Active not recruiting 3 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Biopsy Procedure, Blood Sample, Bone Scan - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2016-02-12 | 2026-11-18 |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Active not recruiting | Kami Maddocks, MD | 48 | 2014-03-26 | 2026-07-22 |
| Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study - BRAF Gene Mutation, Hepatic Complication | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2013-08-23 | 2018-08-14 |
| Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors dabrafenib, pazopanib hydrochloride, Correlative studies - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Manisha Shah | 23 | 2012-11-19 | 2019-03-01 |
| Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies capecitabine, celecoxib, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | University of Chicago | 21 | 2012-08-29 | 2018-05-30 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride - Leydig Cell Tumor, Ovarian Sarcoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 12 | 2012-05-01 | 2015-08-04 |
| Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy Pharmacogenomics testing for clopidogrel responsiveness - Stroke, Transient Ischemic Attack | Phase 1 | Completed | University of North Carolina, Chapel Hill | 48 | 2011-12-01 | 2012-06-08 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-01-01 | 2015-08-27 |
| Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) carfilzomib, Cytokine Assessment, Pharmacodynamic Studies - B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 21 | 2010-10-01 | 2016-05-09 |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Nebraska | 29 | 2010-09-14 | 2023-12-26 |
| Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy - Diffuse Intrinsic Pontine Glioma | Phase 1 | Completed | Centre Oscar Lambret | 32 | 2010-09-06 | 2026-03-16 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2010-05-01 | 2015-11-04 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacogenomic studies - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2010-02-01 | 2014-04-02 |
| Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study - Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2009-11-03 | 2026-09-14 |
| RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2009-11-01 | 2015-04-15 |
| Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride sorafenib tosylate, everolimus, laboratory biomarker analysis - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Roswell Park Cancer Institute | 12 | 2009-08-01 | 2022-09-13 |
| ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme temozolomide, veliparib, DNA methylation analysis - Brain and Central Nervous System Tumors | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2009-07-13 | 2018-06-27 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
Showing 20 of 25. Sign in to see all of them.
Breast Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Prolymphocytic (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Large-Cell, Anaplastic (2)
National Cancer Institute (NCI) (9) · Amir Mortazavi (1) · Cancer Research UK (1) · Case Comprehensive Cancer Center (1) · Centre Oscar Lambret (1) · City of Hope Medical Center (1) · Kami Maddocks, MD (1) · Manisha Shah (1) · Mayo Clinic (1) · National Cancer Centre, Singapore (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Chicago (1) · University of Nebraska (1)
United States (21) · Canada (2) · France (1) · Singapore (1) · United Kingdom (1)
Patricia LoRusso (3) · Amir Mortazavi, MD (1) · Andrea E Wahner Hendrickson (1) · Charles Rudin (1) · Jean Grem (1) · Jeffrey Jones (1) · Jennifer Woyach, MD (1) · Johann Sebastian de Bono, MD (1) · Kami Maddocks, MD (1) · Larry Kleinberg, MD (1) · Laura Chow (1) · Lillian Siu (1) · Manish R. Sharma, M.D. (1) · Manisha Shah, MD (1)
PMID 25355819, PMID 26242208, PMID 26928328, PMID 26943915, PMID 28270022, PMID 28654574, PMID 30181415, PMID 33492438
P30CA022453 (3), U01CA062487 (3), P30CA015083 (2), P30CA016058 (2), U01CA062490 (2), U01CA069912 (2), U01CA070095 (2), U01CA132123 (2), UM1CA186686 (2), UM1CA186690 (2), UM1CA186691 (2), UM1CA186717 (2), 2009 (1), P30CA015704 (1), P30CA033572 (1)